DOCSLIB.ORG

View Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View Annual Report Annual Report Key Figures 2012 Group sales 45,499 millions of CHF +4% (CER) 1 Core operating profit 17,160 millions of CHF +11% (CER) Core earnings per share 13.62 CHF +10% (CER) Operating free cash flow 15,389 millions of CHF +10% (CER) R & D investment 8,475 millions of CHF +2% (CER) Dividend 2 7.35 CHF +8% (CER) Total Shareholder Return 2012 The value of CHF 100 3 invested 1/1/2012, for the period ending 31/12/2012 125 121 120 118 117 115 110 105 100 95 90 Dec Mar Jun Sep Dec 2011 2012 Roche GS, Price = 184.00 Roche B, Price = 186.90 Peer Set Index Patients on clinical trials 326,642 patients +10.4% Number of employees 4 82,089 employees +2.4% 1 CER: Constant exchange rates (average full-year 2011). 2 Proposed by the Board of Directors. 3 Prices translated at constant CHF exchange rates: USD=0.90; EUR=1.20; 100 JPY=1.10; GBP=1.40. 4 Full-time equivalents. Key Events 2012 Roche Group At the Roche Annual General Management changes: 3% Meeting in 2012, shareholders Daniel O’Day, former Head authorised a 3% dividend of Roche Diagnostics, was Daniel O’Day Daniel increase to CHF 6.80 per appointed the new Head of share and non-voting equity. Roche Pharma. Roland DiggelmannRoland It was the company’s 25 th Diggelmann has assumed dividend increase in as many the position of Head of years. Roche Diagnostics. Roche continued to streamline Our late-stage pipeline its research and develop- made considerable progress ment activities, taking the in 2012, with 11 out of 14 clini- decision to close its site in cal trials delivering positive Nutley, New Jersey, USA. results, underpinning the The respective R & D activities strength of our innovation are being consolidated in strategy. Switzerland and Germany. Pharmaceuticals The FDA approved The FDA approved Perjeta Erivedge (vismodegib), (pertuzumab) for patients a first-in-class Hedgehog with HER2-positive meta- Pathway Inhibitor for static breast cancer. This new adults with advanced personalised medicine gives basal cell carcinoma. patients more time without their disease worsening. New data from the Phase III After the second interim EMILIA study showed that data analysis of the Roche’s trastuzumab dal-OUTCOMES trial, Roche emtansine (T–DM1) decided to discontinue the significantly improved survival development of dalcetrapib, of people with HER2-positive a medicine to lower cardio- metastatic breast cancer. vascular risks. Roche has filed for approval at the FDA and the EMA. Corporate Sustainability In 2012 we reduced our The second Transnet- water consumption by 8.6% Phelophepa Healthcare and our greenhouse gas Train was inaugurated in emissions by 2.6%. With this, South Africa. Roche doubled we are well on track to reach its support, now reaching our five-year goal of a 10% over 550,000 people a year in improvement in efficiency by rural South Africa through 2014. the train’s various services. Roche has been recognised Roche has been named as a great place to work, Healthcare Supersector achieving top rankings in Leader in the Dow Jones prestigious award listings Sustainability Indexes (DJSI) worldwide in 2012. for the fourth consecutive year. The ranking is a confir- mation of Roche’s commit- ment to long-term sustainable value creation. Diagnostics New US guidelines recognise The FDA cleared the the benefit of genotyping Accu-Chek Combo the human papillomavirus system, Roche’s new inter- (HPV) 16 and 18, the active insulin pump system principal causes of cervical for people with diabetes, cancer in women. and the Accu-Chek Nano SmartView system. Roche Applied Science Roche launched GUIDE-IT, and Diabetes Care initiated a clinical trial involving the restructuring measures cardiac marker NT-proBNP to sustain long-term profit- to guide therapy in heart ability. failure patients. The value of innovation ROCHE AT A GLANCE Who we are At Roche, we focus on fitting treatments to patients through innovative medicines and diagnostic tests. A global leader in innovation A sustainable company A great workplace Roche is a leader in research-focused We are committed to sustainability and to We are driven by a shared set of stan- healthcare with combined strengths in running our business in a way that is dards of integrity, the courage to reach pharmaceuticals and diagnostics. ethical, responsible and creates long-term beyond boundaries and a passion for value. what we do. 150+ 18,000,01 00 82,0892 countries patients treated employees 18 326,642 26 research centres patients in clinical trials manufacturing sites #1 in biotech #1 in oncology #1 in in vitro diagnostics #1 in hospital market What we do Pharmaceuticals Diagnostics We are the world’s largest biotech company with a product We are the global leader in in vitro diagnostic testing for portfolio of truly differentiated therapies and a robust pipeline early detection, evaluation and monitoring of disease. of investigational new medicines. We are also a frontrunner in the management of diabetes. Sales by therapeutic area 2012 (CER) 3 Sales by business area 2012 (CER) 3 61% Oncology (+9%) 51% Professional Diagnostics (+8%) 9% Virology (+14%) 25% Diabetes Care (–4%) Inflammation/Autoimmune/ 9% Transplantation (+5%) 11% Molecular Diagnostics (+4%) 5% Metabolism/Bone (–23%) 7% Applied Science (–3%) 4% Ophthalmology (–8%) 6% Tissue Diagnostics (+12%) 3% Respiratory diseases (+9%) 3% Cardiovascular diseases (+6%) 2% Renal anemia (–16%) 2% Central nervous system (+1%) 1% Infectious diseases (–1%) 1% Other therapeutic areas (–14%) Pharmaceuticals Sales 35.2 billion CHF Diagnostics Sales 10.3 billion CHF Roche Group Sales 45.5 billion CHF 1 With one of Roche’s 25 top-selling products. 2 Full-time equivalents (FTE). 3 CER: Constant Exchange Rates (average full-year 2011). Our strategic priorities Patients in need We strive to help patients in need with truly differ- cancer 29 million entiated diagnostics and medicines. Our focus lies in five disease areas with unmet medical need, hepatitis C 70 million oncology, inflammation, infectious disease, metabolism and the central nervous system. 24 million schizophrenia 235 million asthma 346 million diabetes Personalised Healthcare Personalised Healthcare at Roche is about providing the right therapy for the right group of patients at PERSONALISED Pharmaceuticals Diagnostics the right time. We provide medicines and diagnostics HEALTHCARE that optimise patient care, enabling tangible improve- ments in health, quality of life and survival. Excellence in science Roche is a highly innovative healthcare company, IN-HOUSE CUTTING EDGE SCIENCE with a robust R & D foundation. We have three autono- mous research units, as well as 150 partnerships OPTIMAL RESOURCE ALLOCATION all over the world, to foster diversity of research and translate science into medicines. EXTERNAL INNOVATION Innovative pricing models E STABLISHED Roche aims to bring its medicines and diagnostic marKETS Pressure from more tests to as many patients in need as possible. active payers To do this, we explore innovative pricing models and patient access schemes targeted to individual markets. E MERGING marKETS Build-up of healthcare systems with tight cost parameters Stakeholder value By discovering and developing innovative products, PATIENTS EMPLOYEES we aim to provide value to all our stakeholders, be they patients, doctors, employees, investors or value FOR society as a whole. ALL staKEHOLDERS SHAREHOLDERS PROVIDERS TP O -SELLING pharmaceuticals in millions of CHF 6,707 5,889 5,764 1,649 1,523 Product MabThera/ Herceptin Avastin Pegasys Xeloda Rituxan Sales growth (CER) 1 +9% +11% +6% +12% +9% Active substance rituximab trastuzumab bevacizumab peginterferon alfa-2a capecitabine Indications non-Hodgkin’s lymphoma, HER2-positive breast colorectal cancer, breast hepatitis B and C colorectal cancer, chronic lymphocytic cancer, advanced HER2- cancer, non-small cell colon cancer, leukemia, rheumatoid positive stomach cancer lung cancer, kidney breast cancer arthritis, ANCA-asso- cancer, ovarian cancer, ciated vasculitis glioblastoma 1 CER: Constant exchange rates (average full-year 2011). TP O -SELLING diagnostics in millions of CHF Accu-Chek Nano SmartView cobas e 602 cobas c 502 cobas TaqMan 48 Ventana IHC reagents 2,346 2,321 1,514 562 518 Product Accu-Chek cobas e modules, cobas c modules, Cobas AmpliPrep/ immunohistochemistry monitoring systems Modular Analytics, Modular Analytics, Cobas TaqMan and in situ hybridisation Elecsys Cobas Integra Sales growth (CER) 1 –5% +15% +5% +2% +13% Market segment Blood glucose monitoring Immunoassays Clinical chemistry Virology (hepatitis B, Advanced tissue staining hepatitis C, HIV) Business area Diabetes Care Professional Diagnostics Professional Diagnostics Molecular Diagnostics Tissue Diagnostics The Value of Innovation Roche is a global leader in innovation for medicines and diagnostic testing. This annual report highlights how inno- vation brings value to patients, prescribers, healthcare reimbursement and society as a whole. 16 58 70 A possible new medicine Actemra/Roactemra High-sensitivity for HER2-positive meta- Relief for the agony of childhood cardiac test static breast cancer arthritis Precise testing for life or A new generation of cancer death decisions treatment 78 88 98 Accurate diagnosis and Working with the insurance cobas HPV and CINtec personalised healthcare industry in China tests Focusing healthcare budgets Improving health insurance Better screening for cervical on targeted treatments coverage for cancer patients cancer 106 120 Special Feature The fight against cancer goes on From mining to biotech - Innovation in the pharma- 50 years of cancer research at Roche One in three people will develop cancer during their lifetime. From the start, our aim was to advance the treatment of cancer. And yet the challenge to find a cure remains elusive. One of the As a result, Roche later developed several successor drugs Roche Penzberg ceutical industry reasons it is so difficult to treat is that cancer is, strictly speak- with the aim of preferentially generating the cytotoxin 5-FU in ing, not just one disease but a group of different diseases.
Load more

Recommended publications
  • Inflammation and Cardiometabolic Risk
    Official Publication of the National Lipid Association LipidSpin Inflammation and Cardiometabolic Risk Also in this issue: Clinical Trial Evidence for the Role of Reducing Inflammation for Cardiovascular Disease Prevention Identifying and Managing the Patient with High Inflammatory Burden Dietary Patterns and Systemic Inflammation: Examining the Connection This issue is sponsored by the Pacific Lipid Association. Volume 17 Issue 1 2019 visit www.lipid.org NATIONAL LIPID ASSOCIATION Turnberry Isle Miami 19999 W. Country Club Dr. SCIENTIFIC 9 Aventura, FL 33180 1 SESSIONS Group Rate: $229/night++ 0 Reservation Cut-Off Date: MIAMI 2 April 14, 2019 Pre-Conference Courses | May 15-16 Make your plans to join the NLA in 2019 for these premier events! lipid.org/conferences FEBRUARY 22-24 SEPTEMBER 13-15 2019 2019 PORTLAND MINNEAPOLIS Hilton Portland Downtown Renaissance Minneapolis Hotel, the Depot 921 SW Sixth Avenue, Portland, OR 97204 225 Third Avenue South, Minneapolis, MN 55401 Group Rate: $185/night++ Group Rate: $179/night++ Reservation Cut-Off Date: January 21, 2019 Reservation Cut-Off Date: August 14, 2019 Pre-Conference Courses | February 21-22, 2019 Pre-Conference Courses | September 12-13, 2019 In This Issue: 2019 (Volume 17, Issue 1) Editors DANIEL E. SOFFER, MD, FNLA* 2 From the NLA President 18 Practical Pearls Clinical Associate Professor of Medicine New Clinical Guidelines: Paving the Top 10 Ways to Reduce Inflammation University of Pennsylvania — Cezary Wójcik, MD, PhD, DSc, FNLA* Internal Medicine and Preventive Cardiology Road Ahead University of Pennsylvania Health System — Alan S. Brown, MD, FNLA* Philadelphia, PA — Daniel E. Soffer MD, FNLA* — Kaye-Eileen Willard MD, FNLA* KAYE-EILEEN WILLARD, MD, FNLA* 20 Case Study Medical Director, Lipid Clinic and Physician Advisor Identifying and Managing the Patient Ascension Wisconsin All Saints Racine, WI 4 From the PLA President with High Inflammatory Burden President’s Views — Michelle Taylor, CCRN, ANP Associate Editors — Nathan D.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Monovalent Antibody Design and Mechanism of Action of Onartuzumab, a MET Antagonist with Anti-Tumor Activity As a Therapeutic Ag
    Monovalent antibody design and mechanism of PNAS PLUS action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Mark Merchanta,1,2, Xiaolei Mab,2,3, Henry R. Maunc,2, Zhong Zhenga,2,4, Jing Penga, Mally Romeroa,5, Arthur Huangd,6, Nai-ying Yanga, Merry Nishimuraa, Joan Grevee, Lydia Santellc, Yu-Wen Zhangf, Yanli Suf, Dafna W. Kaufmanf, Karen L. Billecig, Elaine Maih, Barbara Moffatg,7, Amy Limi, Eileen T. Duenasi, Heidi S. Phillipsa, Hong Xiangj, Judy C. Youngh, George F. Vande Woudef, Mark S. Dennisd, Dorothea E. Reillyk, Ralph H. Schwalla,8, Melissa A. Starovasnikb, Robert A. Lazarusc, and Daniel G. Yansurad Departments of aTranslational Oncology, bStructural Biology, cEarly d e Discovery Biochemistry, Antibody Engineering, Biomedical Imaging, fi gProtein Chemistry, hBiochemical and Cellular Pharmacology, iPurification Signi cance Development, jPharmacokinetic and Pharmacodynamic Sciences, and kEarly Stage Cell Culture, Genentech, Inc., South San Francisco, CA 94080; and Therapeutic antibodies have revolutionized the treatment of hu- fLaboratory of Molecular Oncology, Van Andel Research Institute, Grand Rapids, MI 49503 man disease. Despite these advances, antibody bivalency limits their utility against some targets. Here, we describe the de- Edited by Richard A. Lerner, The Scripps Research Institute, La Jolla, CA, and velopment of a one-armed (monovalent) antibody, onartuzumab, approved June 3, 2013 (received for review February 15, 2013) targeting the receptor tyrosine kinase MET. While initial screening Binding of hepatocyte growth factor (HGF) to the receptor tyrosine of bivalent antibodies produced agonists of MET, engineering kinase MET is implicated in the malignant process of multiple can- them into monovalent antibodies produced antagonists instead.
    [Show full text]
  • Phase I Dose-Escalation Study of Onartuzumab As a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
    Published OnlineFirst February 3, 2014; DOI: 10.1158/1078-0432.CCR-13-2070 Clinical Cancer Cancer Therapy: Clinical Research Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies Ravi Salgia1, Premal Patel2, John Bothos2, Wei Yu2, Steve Eppler2, Priti Hegde2, Shuang Bai2, Surinder Kaur2, Ihsan Nijem2, Daniel V.T. Catenacci1, Amy Peterson2, Mark J. Ratain1, Blase Polite1, Janice M. Mehnert3, and Rebecca A. Moss3 Abstract Purpose: This first-in-human study evaluated the safety, immunogenicity, pharmacokinetics, and antitumor activity of onartuzumab, a monovalent antibody against the receptor tyrosine kinase MET. Experimental Design: This 3þ3 dose-escalation study comprised three stages: (i) phase Ia dose escalation of onartuzumab at doses of 1, 4, 10, 20, and 30 mg/kg intravenously every 3 weeks; (ii) phase Ia cohort expansion at the recommended phase II dose (RP2D) of 15 mg/kg; and (iii) phase Ib dose escalation of onartuzumab at 10 and 15 mg/kg in combination with bevacizumab (15 mg/kg intravenously every 3 weeks). Serum samples were collected for evaluation of pharmacokinetics, potential pharmaco- dynamic markers, and antitherapeutic antibodies. Results: Thirty-four patients with solid tumors were treated in phase Ia and 9 in phase Ib. Onartuzumab was generally well tolerated at all dose levels evaluated; the maximum tolerated dose was not reached. The most frequent drug-related adverse events included fatigue, peripheral edema, nausea, and hypoalbumi- nemia. In the phase Ib cohort, onartuzumab at the RP2D was combined with bevacizumab and no dose- limiting toxicities were seen.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Trastuzumab Emtansine (T-DM1)
    Published OnlineFirst September 11, 2018; DOI: 10.1158/1078-0432.CCR-18-1590 Research Article Clinical Cancer Research Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers Solange Peters1, Rolf Stahel2, Lukas Bubendorf3, Philip Bonomi4, Augusto Villegas5, Dariusz M. Kowalski6, Christina S. Baik7, Dolores Isla8, Javier De Castro Carpeno9, Pilar Garrido10, Achim Rittmeyer11, Marcello Tiseo12, Christoph Meyenberg13, Sanne de Haas14, Lisa H. Lam15, Michael W. Lu15, and Thomas E. Stinchcombe16 Abstract Purpose: HER2-targeted therapy is not standard of care Results: Forty-nine patients received T-DM1 (29 IHC 2þ, for HER2-positive non–small cell lung cancer (NSCLC). This 20 IHC 3þ). No treatment responses were observed in the phase II study investigated efficacy and safety of the HER2- IHC 2þ cohort. Four partial responses were observed in the targeted antibody–drug conjugate trastuzumab emtansine IHC 3þ cohort (ORR, 20%; 95% confidence interval, 5.7%– (T-DM1) in patients with previously treated advanced 43.7%). Clinical benefit rates were 7% and 30% in the IHC HER2-overexpressing NSCLC. 2þ and 3þ cohorts, respectively. Response duration for the Patients and Methods: Eligible patients had HER2-over- responders was 2.9, 7.3, 8.3, and 10.8 months. Median expressing NSCLC (centrally tested IHC) and received progression-free survival and overall survival were similar previous platinum-based chemotherapy and targeted between cohorts. Three of 4 responders had HER2 gene therapy in the case of EGFR mutation or ALK gene amplification. No new safety signals were observed. rearrangement. Patients were divided into cohorts based Conclusions: T-DM1 showed a signal of activity in patients on HER2 IHC (2þ,3þ).
    [Show full text]
  • US10851148.Pdf
    US 10,851,148 B2 Page 2 ( 56 ) References Cited Hue et al , “ Potential Role of NKG2D / MHC Class I - Related Chain A Interaction in Intrathymic Maturation of Single - Positive CD8 T Cells , " J Immunol. 171 : 1909-1917 ( 2003 ) . OTHER PUBLICATIONS Hue S , et al . , " A Direct Role for NKG2D / MICA Interaction in Villous Atrophy during Celiac Disease , " Immunity 21 : 367-377 Bahram et al . , “ Nucleotide sequence of the human MHC class I ( 2004 ) . MCA gene, ” Immunogenetics 44 : 80-81 ( 1996 ) . Jimenez - Perez et al . , “ Cervical cancer cell lines expressing Bahram et al . , “ Nucleotide sequence of a human MHC class I MICB NKG2Dligands are able to down -modulate the NKG2D receptor on cDNA , ” Immunogenetics 43 : 230-233 ( 1996 ) . NKL cells with functional implications, ” BMC Immunology 13 : 7 Barlow et al ., “ Continuous and discontinuous antigenic determi ( 2012 ) . nants, ” Nature 322 : 747-748 ( 1986 ) . Jinushi et al . , “ Therapy - induced antibodies to MHC class I chain Bauer et al . , “ Expression and purification , crystallization and crys related protein A antagonize immune suppression and stimulate tallographic characterization of the human MHC class 1 related antitumor cytotoxicity , ” Proc Natl Acad Sci USA . 103 ( 24 ) :9190 protein MICA , ” Acta Cryst D54 : 451-453 ( 1998 ) . 9195 ( 2006 ) . Bauer et al ., “ Activation of NK Cells and T Cells by NKG2D , a Jinushi et al . , “ MHC class I chain - related protein A antibodies and Receptor for Stress - Inducible MICA , " Science 285 ( 5428 ) : 727-9 shedding are associated with the progression of multiple myeloma , " ( 1999 ) . Proc Natl Acad Sci USA . 105 ( 4 ) : 1285-1290 ( 2008 ) . Boissel et al . , “ BCR ABL Oncogene Directly Controls MHC Class Jonjic et al .
    [Show full text]
  • Small-Cell Lung Cancer: Evidence to Date Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaid
    Targeting the MET-Signaling Pathway in Non- Small-Cell Lung Cancer: Evidence to Date Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaid To cite this version: Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaid. Targeting the MET-Signaling Pathway in Non- Small-Cell Lung Cancer: Evidence to Date. OncoTargets and Therapy, Dove Medical Press, 2020, Volume 13, pp.5691-5706. 10.2147/OTT.S219959. hal-02886104 HAL Id: hal-02886104 https://hal.sorbonne-universite.fr/hal-02886104 Submitted on 1 Jul 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Targeting the MET-Signaling Pathway in Non- Small–Cell Lung Cancer: Evidence to Date This article was published in the following Dove Press journal: OncoTargets and Therapy Olivier Bylicki 1,2 Abstract: The c-MET proto-oncogene (MET) plays an important role in lung oncogenesis, Nicolas Paleiron1 affecting cancer-cell survival, growth and invasiveness. The MET receptor in non-small–cell – Jean-Baptiste Assié2 4 lung cancer (NSCLC) is a potential therapeutic target. The development of high-output next- fi Christos Chouaïd2,3 generation sequencing techniques has enabled better identi cation of anomalies in the MET pathway, like the MET exon-14 (METex14) mutation.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Study on Stabilization of Human Igg4 Antibodies
    九州大学学術情報リポジトリ Kyushu University Institutional Repository Study on stabilization of human IgG4 antibodies 浪崎, 博史 https://doi.org/10.15017/2534401 出版情報：九州大学, 2019, 博士（創薬科学）, 課程博士 バージョン： 権利関係： ヒト IgG4 抗体の安定化に関する研究 Study on stabilization of human IgG4 antibodies 2019 九州大学 大学院薬学府 臨床薬学部門 細胞生物薬学分野 浪崎 博史 1 略語表 CD; cluster of differentiation Ig; Immunoglobulin CDR; complementary determining region V; variable D; diversity J; joining RAG; recombination-activating gene RSS; recombination signal sequences TdT; terminal deoxynucleotidyl-transferase AID; activation induced cytidine deaminase BCR; B cell receptor TCR; T cell receptor Fab; fragment, antigen binding Fc; Fragment, Crystallizable VH; variable heavy CH; constant heavy VL; variable light CL; constant light CDC; complement-dependent cytotoxicity ADCC; antibody-dependent cellular cytotoxicity ADCP; antibody-dependent cellular phagocytosis NK; natural killer FcγR; Fc gamma receptor ITAM; immunoreceptor tyrosine-based activation motif 2 ITIM; immunoreceptor tyrosine-based inhibitory motif FcRn; neonatal Fc receptor PD-1; programmed cell death 1 PD-L1; programmed cell death –lignd1 VLA4; very late antigen-4 DNP; dinitrophenol ELISA; Enzyme-linked immunosorbent assay KD; dissociation constant SEC; size-exclusion chromatography DSF; differential scanning fluorimetry DSC; differential scanning calorimetry Tm; melting transition RU; resonance unit 3 目次 第一章 序論 p.5 １－１ 背景 p.5 １－１－１ 免疫グロブリンの種類および機能 p.5 １－１－２ 免疫グロブリンの多様性獲得 p.7 １－１－３ ヒト IgG の構造および機能 p.9 １－１－４ 抗体医薬の開発および承認状況 p.13 １－１－５ ヒト IgG4 の抗体医薬の研究開発状況 p.17 １－１－６ ヒト IgG サブクラスにおける安定性 p.21 １－２ 引用文献 p.25 第二章 ヒト IgG4 抗体の低 pH 誘導性凝集体形成における アミノ酸改変による抑制効果に関する研究 p.30 ２－１ 要旨 p.30 ２－２ 研究背景 p.32 ２－３ 材料および方法 p.35 ２－４ 結果 p.43 ２－５ 考察 p.78 ２－６ 引用文献 p.87 謝辞 p.94 4 第一章 序論 １－１ 背景 １－１－１ 免疫グロブリンの種類および機能 免疫グロブリン（Immunoglobulin；Ig）は哺乳細胞に存在する B 細胞から産生される 糖タンパク質であり、外来抗原を認識して結合する機能を有する。Ig は主に血液中 および組織体液中に存在し、細菌やウイルスなどの外来抗原に結合することにより、 白血球またはマクロファージによる食作用、ならびに免疫細胞の結合による免疫作 用により生体防御に関わっている。ヒトの免疫グロブリンは、IgG, IgA, IgM, IgD お よび IgE の 5 つのクラスが存在し (Fig.
    [Show full text]
  • Immunopet Detects Changes in Multi-RTK Tumor Cell Expression Levels In
    Journal of Nuclear Medicine, published on July 9, 2020 as doi:10.2967/jnumed.120.244897 ImmunoPET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition Patricia M. R. Pereira1*, Jalen Norfleet1, Jason S. Lewis1,2,3,4,5, Freddy E. Escorcia6* Affiliations: 1 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 2 Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA 3 Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA 4 Department of Radiology, Weill Cornell Medical College, New York, NY, USA 5 Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA 6 Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA Word count: 4999 Running Title: ImmunoPET Detects Response to Therapy Key words: ImmunoPET, molecular imaging, kinases, oncology, theranostics *Corresponding authors: Freddy E. Escorcia, MD/PhD. Molecular Imaging Program, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20814. [email protected] P: 240-858-3062 Patricia M.R. Pereira , PhD. Memorial Sloan Kettering Cancer Center. 1275 York Ave, New York, NY 10065. [email protected] P: 646-888-2763 Disclosures: Investigators obtained onartuzumab from Genentech, otherwise, no relevant conflicts of interest. Financial Support: The Radiochemistry and Molecular Imaging Probe Core and the Anti-tumor Assessment Core, were supported by NIH, grant P30 CA08748. This study was supported in part by the Geoffrey Beene Cancer Research Center of MSKCC (JSL), NIH NCI R35 CA232130 (JSL), and ZIA BC 011800 (FEE).
    [Show full text]